MANAGEMENT OF COMPARTMENT SYNDROME WITH ULTRAFILTRATION

超滤治疗筋膜室综合征

• 批准号: 6310846
• 负责人: RICK M ODLAND
• 金额: $ 56.52万
• 依托单位: TWIN STAR MEDICAL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6310846
• 关键词: biomedical equipment development; disease /disorder prevention /control; edema; human subject; interstitial; limbs; medical complication; microdialysis; necrosis; patient oriented research; swine; syndrome; trauma

DESCRIPTION (Verbatim from the Applicant's Abstract): Compartment Syndrome (CS) is a condition of high tissue pressure causing ischemia damaging muscles and nerves. It is known that in highly non-compliant tissues a small fluid volume decrease can produce a large pressure drop, and thereby increase perfusion and improve circulation and oxygenation. During Phase I, we demonstrated feasibility of an innovative use of tissue ultrafiltration (UF) to reduce tissue pressure by removing interstitial and/or intracellular fluid volume, and to use the increased fluid levels of metabolites to improve diagnosis. 77'e central hypothesis is that UF catheters in muscle compartments can be used to improve functional outcome in CS, by improving diagnosis and reducing intramuscular pressure. In Phase II, bench, animal and human studies have been designed to further develop UF as a clinical tool. Patients will not be placed at higher risk of CS sequelae since UF has limited invasiveness, a history of safety as an assay tool, and does not pre-empt eventual fasciotomy should clinical signs and symptoms warrant. Our expectation is that clinical application of CSUF will provide earlier diagnosis, less morbid treatment, and will prevent sequelae of untreated CS. Expected US healthcare cost savings from the use of CSUF are $200 million per year. PROPOSED COMMERCIAL APPLICATION: Not Available

描述（来自申请人摘要的逐字描述）：昏迷综合征（CS） 是一种高组织压力的情况，导致局部缺血损伤肌肉， 神经已知在高度非顺应性组织中， 减少可以产生大的压降，从而增加灌注， 改善循环和氧合。在第一阶段，我们展示了 组织超滤（UF）的创新使用的可行性，以减少 通过去除组织间液和/或细胞内液体积来对组织加压，以及 利用体液中代谢物含量的增加来提高诊断水平。77 'e 中心假设是，肌肉室中的UF导管可用于 通过改善诊断和减少 肌肉压力在第二阶段，实验室、动物和人体研究已经完成。 旨在进一步发展UF作为临床工具。患者将不会被安置在 CS后遗症的风险较高，因为UF的侵入性有限， 安全性作为一种分析工具，并不预先采取最终筋膜切开术， 临床症状和体征。我们的期望是， CSUF的应用将提供早期诊断，减少病态治疗， 将防止未经治疗的CS的后遗症。预计美国医疗保健成本节省， CSUF的使用每年为2亿美元。 拟定商业应用： 不可用